NEWBRY — Newbury Pharmaceuticals AB Share News
0.000.00%
Last trade - 00:00- SEK63.23m
- SEK48.55m
- SEK31.57m
Brief: Newbury Pharmaceuticals Prelim Q4 Sales At SEK 20 Mln
Brief: Newbury Pharmaceuticals Secures Approval For Varenicline In Sweden
Brief: Newbury Pharmaceuticals Starts DCP Filing For Teduglutide On Day-1 Following Expiry Of Data Exclusivity
Brief: Newbury Pharmaceuticals Q3 EBITDA Loss Widens To SEK 7.9 Mln
Brief: Newbury Pharmaceuticals Secures Generic Approval For Liraglutide Pre-Filled Pen
Brief: Newbury Pharmaceuticals Strengthens Portfolio With Dalbavancin Powder
Brief: Newbury Pharmaceuticals Q2 Net Revenue Up At Sek 3.1 Mln
Brief: Newbury Pharmaceuticals Q2 EBITDA at SEK -4.15 Million
Brief: Newbury Pharmaceuticals Carries Out Directed Share Issue Of SEK 19 Mln
Brief: Newbury Pharmaceuticals Gets Sales Order Valued At SEK 8.8 Mln
Brief: Newbury Pharmaceuticals Q1 Net Revenue SEK 11,185
Brief: Newbury Pharmaceuticals Strengthens Portfolio With Melatonin Extended Release 2 Mg
Brief: Newbury Pharmaceuticals Q4 EBITDA Loss Widens To SEK 4.5 Mln
Brief: Newbury Pharma Enters Partnership To Commercialize Registered Products
Brief: Newbury Pharmaceuticals Adds Levodopa/Benserazide To Portfolio
Brief: Newbury Pharmaceuticals Signs SEK 15 Mln Loan Agreement
Brief: Newbury Signs Strategic Partnership For Prescription Medicine
Brief: Desmopressin Newbury Approved By Swedish Health Authorities
Brief: Newbury Pharmaceuticals Sets Financial Goals For 2024 And 2028